Abstract:Idiopathic pulmonary fibrosis (IPF) is characterized by permanent scarring of lung tissue and declining lung function, and is an incurable disease with increase in prevalence over the past decade. The current consensus is that aberrant wound healing following repeated injuries to the pulmonary epithelium is the most probable cause of IPF, with various immune inflammatory pathways having been reported to impact disease pathogenesis. While the role of immune cells, specifically T lymphocytes and regulatory T cells (Treg), in IPF pathogenesis has been reported and discussed recently, the pathogenic or beneficial roles of these cells in inducing or preventing lung fibrosis is still debated. This lack of understanding could be due in part to the difficulty in obtaining diseased human lung tissue for research purposes. For this reason, many animal models have been developed over the years to attempt to mimic the main clinical hallmarks of IPF: among these, inducing lung injury in rodents with the anti-cancer agent bleomycin has now become the most commonly studied animal model of IPF. Pulmonary fibrosis is the major side effect when bleomycin is administered for cancer treatment in human patients, and a similar effect can be observed after intra-tracheal administration of bleomycin to rodents. Despite many pathophysiological pathways of lung fibrosis having been investigated in bleomycin-injured animal models, one central facet still remains controversial, namely the involvement of specific T lymphocyte subsets, and in particular Treg, in disease pathogenesis. This review aims to summarize the major findings and conclusions regarding the involvement of immune cells and their receptors in the pathogenesis of IPF, and to elaborate on important parallels between animal models and the human disease. A more detailed understanding of the role of Treg and other immune cell subsets in lung injury and fibrosis derived from animal models is a critical basis for translating this knowledge to the development of new immune-based therapies for the treatment of human IPF.

Updates on the controversial roles of regulatory lymphoid cells in idiopathic pulmonary fibrosis

Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis?

Allies or enemies? The effect of regulatory T cells and related T lymphocytes on the profibrotic environment in bleomycin-injured lung mouse models

T cells in idiopathic pulmonary fibrosis: crucial but controversial

The role of immune response in the pathogenesis of idiopathic pulmonary fibrosis: far beyond the Th1/Th2 imbalance

The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis

Emerging role of immune cells as drivers of pulmonary fibrosis

Regulatory T Cells Are a Double-Edged Sword in Pulmonary Fibrosis.

The Role of Immune Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis

Role of Immune Cells in the Initiation and Progression of Pulmonary Fibrosis

The potential role of interleukin (IL)-25/IL-33/thymic stromal lymphopoietin (TSLP) on the pathogenesis of idiopathic pulmonary fibrosis

Interpreting Immunoregulation in Lung Fibrosis: A New Branch of the Immune Model

Activation of the P2RX7/IL-18 pathway in immune cells attenuates lung fibrosis

Immune cells crosstalk Pathways, and metabolic alterations in Idiopathic pulmonary fibrosis

B-cell Activating Factor Regulates IL-1β- and IL-17A-mediated Pulmonary Fibrosis in Mice

The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?

Revisiting the role of MicroRNAs in the pathogenesis of idiopathic pulmonary fibrosis

TGF-1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review)

Role of transient receptor potential ankyrin 1 in idiopathic pulmonary fibrosis: modulation of M2 macrophage polarization

Toll-like receptor 4 activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with IPF.

Toll-like receptors in the pathogenesis of pulmonary fibrosis